A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer

Xiujuan Wu; Peng Tang; Shifei Li; Shushu Wang; Yueyang Liang; Ling Zhong; Lin Ren; Ting Zhang; Yi Zhang

doi:10.1038/s41467-018-03210-2

Nature Communications (Feb 2018)

A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer

Xiujuan Wu,
Peng Tang,
Shifei Li,
Shushu Wang,
Yueyang Liang,
Ling Zhong,
Lin Ren,
Ting Zhang,
Yi Zhang

Affiliations

Xiujuan Wu: Breast Disease Center, Southwest Hospital, Third Military Medical University
Peng Tang: Breast Disease Center, Southwest Hospital, Third Military Medical University
Shifei Li: Breast Disease Center, Southwest Hospital, Third Military Medical University
Shushu Wang: Breast Disease Center, Southwest Hospital, Third Military Medical University
Yueyang Liang: Breast Disease Center, Southwest Hospital, Third Military Medical University
Ling Zhong: Breast Disease Center, Southwest Hospital, Third Military Medical University
Lin Ren: Breast Disease Center, Southwest Hospital, Third Military Medical University
Ting Zhang: Breast Disease Center, Southwest Hospital, Third Military Medical University
Yi Zhang: Breast Disease Center, Southwest Hospital, Third Military Medical University

DOI: https://doi.org/10.1038/s41467-018-03210-2
Journal volume & issue: Vol. 9, no. 1
pp. 1 – 8

Abstract

Read online

Triple-negative breast cancer (TNBC) is one of the most aggressive and difficult to treat types of breast cancer. Here, a phase 2 clinical trial in TNBC patients reveals that the addition of lobaplatin to docetaxel and epirubicin regime improves pCR and ORR rates with tolerable side-effects.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal